Short acting beta agonist inhalers by all Sub-ICB Locations
Why it matters: The BTS/NICE/SIGN guidance has updated guidance on use of short acting beta agonists (SABAs), and states do not prescribe short-acting beta2 agonists to people of any age with asthma without a concomitant prescription of an ICS. In addition, it also recommends that patients aged 12 and over with uncontrolled asthma (e.g. needing a reliever 3 or more days a week) should have their treatment changed to a non SABA-based regimen.
Why Asthma Still Kills reports that high use of SABAs (salbutamol and terbutaline) and poor adherence to inhaled corticosteroids in asthma suggests poor control - these patients should be reviewed regularly to ensure good control.
The NHS England National Medicines Optimisation Opportunities for 2024/25 identify improving patient outcomes from the use of inhalers as an area for improvement.
Description: Number of short acting beta agonist (SABA) inhalers - salbutamol and terbutaline - compared with number of all inhaled corticosteroid inhalers and SABA inhalers
Explore:
Tagged as: Standard, Respiratory, National medicines optimisation opportunities, Safety (or browse all measures)
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.
View measure for NHS England combined →
Fetching data...